Aaron Bravman Muriel Bravman v. Baxter Healthcare Corporation

984 F.2d 71, 1993 U.S. App. LEXIS 993, 1993 WL 13527
CourtCourt of Appeals for the Second Circuit
DecidedJanuary 21, 1993
Docket564, Docket 92-7645
StatusPublished
Cited by25 cases

This text of 984 F.2d 71 (Aaron Bravman Muriel Bravman v. Baxter Healthcare Corporation) is published on Counsel Stack Legal Research, covering Court of Appeals for the Second Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Aaron Bravman Muriel Bravman v. Baxter Healthcare Corporation, 984 F.2d 71, 1993 U.S. App. LEXIS 993, 1993 WL 13527 (2d Cir. 1993).

Opinion

OAKES, Circuit Judge:

Aaron Bravman (“Bravman”) and his wife, Muriel Bravman, appeal from a judgment of the United States District Court for the Southern District of New York, Robert W. Sweet, Judge, granting Baxter Healthcare Corporation (“Baxter”) summary judgment and dismissing Bravman’s amended complaint in a diversity case. The district court determined as a matter of law that Bravman had suffered no physical harm from the implant of a noisy artificial heart valve manufactured by Baxter and did not have a cause of action for the noise and ensuing nervousness and sleeplessness nor for the fear of heart valve failure that the noise engendered. For the reasons set forth below, we affirm in part, reverse in part, and remand with directions. We hold that Bravman does not have a claim for relief under a product or design defect theory of liability. We hold, however, that Bravman is entitled to a jury determination whether the noise emitted by the heart valve caused a cognizable injury and whether Baxter violated a duty to warn Bravman’s doctor of the potential noise.

BACKGROUND

On April 5, 1988, Bravman, a Pennsylvania resident, underwent surgery at New York University Hospital to replace his natural mitral heart valve with an artificial Edwards-Duromedics Heart Valve made by Baxter, an Illinois corporation. Brav-man’s surgery was made necessary by the serious deterioration of his natural heart valve. Dr. Frank Spencer of New York University Hospital performed the surgery. Bravman met once with Dr. Spencer before his operation. At this meeting, Dr. Spencer recommended that Bravman use a mechanical valve rather than a porcine valve, made from natural pig tissue, because of the mechanical valve’s greater longevity. However, Dr. Spencer did not discuss with Bravman the variety of mechanical valves available nor did he warn Bravman about the noise associated with the Edwards-Du-romedics valve.

Bravman’s surgery was successful and his artificial valve continues properly to control the flow of blood into his heart. Nonetheless, Bravman complains of a complication — his valve makes a loud and disruptive noise. Although everyone concedes that all mechanical valves make some noise, Bravman asserts, and is supported in his assertions, that his Edwards-Duromed-ics valve makes an unacceptable amount of noise. In fact, Bravman contends that, in a quiet environment, his heart valve can be heard from a distance of thirty feet. As a consequence of the valve noise, Bravman claims that he cannot sleep, that he is despondent, and that he was obliged to take an early retirement. Bravman states he has even explored the possibility of undergoing additional surgery to replace the valve to eliminate the noise.

Bravman raised four claims for relief before the district court: breach of express warranty, breach of implied warranty, negligence, and strict product liability. After *73 discovery was closed, Baxter filed a motion for summary judgment, requesting that Bravman’s complaint be dismissed with prejudice. The district court granted the motion on the basis that Mr. Bravman’s-fear that his mechanical heart valve was going to fail was legally insufficient to support a claim that he was injured and that the excessive heart valve sounds Brav-man had experienced since his - operation did not support a legally cognizable product defect claim under New York law. Bravman v. Baxter Healthcare Corp., 794 F.Supp. 96 (S.D.N.Y.1992).

On appeal, Bravman raises three issues: first, he contends that the district court erred in concluding as a matter of law that the heart valve noise caused him no physical harm, and, therefore, that he has a valid failure-to-warn claim against Baxter; second, he claims that the district court erred in finding that there was no legally cognizable product defect in his Edwards-Duromedics heart valve; and third, he argues that the district court should have allowed a jury to determine whether a design defect existed in light of evidence that alternative valve designs did not create the same level of noise as the Edwards-Du-romedics heart valve. We find that the determination whether Bravman sustained a physical injury is a disputed question of fact that should not have been resolved on summary judgment; given the disputed evidence in the record on the question of Baxter’s awareness of the noise level, the excessiveness of the noise, and the availability of other mechanical valves with similar functionality and operation at a lower noise level, Bravman’s failure to warn claim is viable. The district court, however, correctly determined that as a matter of law Bravman could not recover under either a product defect or design defect theory of liability.

DISCUSSION

We begin first with Bravman’s claim that Baxter had a duty to warn him that the Edwards-Duromedics heart valve produced excessive noise and that the company violated its duty to warn the relevant medical community about this noise. As the manufacturer of the heart valve, Baxter was obliged “to warn of all potential dangers which it knew, or in the exercise of reasonable care should have known, to exist.” Lindsay v. Ortho Pharmaceutical Corp., 637 F.2d 87, 91 (2d Cir.1980).

Evidence in the record shows that Baxter knew that its Edwards-Duromedics valve tended to be noisy and that the noise generated concern among doctors and complaints among patients. In response, Baxter argues that all mechanical valves necessarily make noise and that the noise actually serves an important diagnostic role by enabling cardiologists to monitor the valve sounds and determine whether the valves are functioning properly. This argument, however, does not rebut the complaint of excessive noise. In particular, Bravman points to two types of noise problems of which Baxter was aware when Bravman received the Edwards-Duromedics valve.

First, there is evidence that at the time of Bravman’s surgery Baxter knew that the Edwards-Duromedics valve made more noise than some other valves that were available on the market at the time of Bravman’s surgery. For example, Baxter had received information from the German Heart Center that the Duromedics valve created more' noise than did a rival valve. 1 The record also includes some evidence that cardiologists familiar with the Edwards-Duromedies valve told Baxter that patients complained about noise from the valve. In 1987, Baxter sponsored a symposium on the Edwards-Duromedics valve at which 22 cardiologists from around the world discussed the valve. At the symposium, at least two cardiologists presented information concerning noise problems with the Edwards-Duromedics valve that *74 doctors had observed in the hospitals where they worked. Both cardiologists suggested that prospective users of the Edwards-Duromedics heart valve should be warned about these potential problems.

Bravman also claims that Baxter knew of a second, apparently infrequent, but more severe noise problem: that the Edwards-Duromedics valve creates extraordinary noise in some patients.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Silva v. Heil, Inc.
E.D. New York, 2023
Andre v. Invenergy LLC
W.D. New York, 2022
Jorge Rico v. Clark Ducart
980 F.3d 1292 (Ninth Circuit, 2020)
Tomaselli v. Zimmer
Second Circuit, 2018
Drake ex rel. J.D. v. Allergan, Inc.
63 F. Supp. 3d 382 (D. Vermont, 2014)
Garrison v. Novartis Pharmaceuticals Corp.
30 F. Supp. 3d 1325 (M.D. Alabama, 2014)
Bee v. Novartis Pharmaceuticals Corp.
18 F. Supp. 3d 268 (E.D. New York, 2014)
Valente v. Textron, Inc.
931 F. Supp. 2d 409 (E.D. New York, 2013)
Ohuche v. Merck & Co.
903 F. Supp. 2d 143 (S.D. New York, 2012)
Davids v. Novartis Pharmaceuticals Corp.
857 F. Supp. 2d 267 (E.D. New York, 2012)
Kellogg v. Wyeth
762 F. Supp. 2d 694 (D. Vermont, 2010)
In Re Bridgestone/Firestone, Inc. Tires Products
155 F. Supp. 2d 1069 (S.D. Indiana, 2001)
Anderson v. Hedstrom Corp.
76 F. Supp. 2d 422 (S.D. New York, 1999)
Mozes v. Medtronic, Inc.
14 F. Supp. 2d 1124 (D. Minnesota, 1998)
Garnsey v. Morbark Industries, Inc.
971 F. Supp. 668 (N.D. New York, 1997)
Golod v. Hoffman La Roche
964 F. Supp. 841 (S.D. New York, 1997)
Tissenbaum v. Aerovias Nacionales De Colombia, S.A.
885 F. Supp. 434 (E.D. New York, 1995)

Cite This Page — Counsel Stack

Bluebook (online)
984 F.2d 71, 1993 U.S. App. LEXIS 993, 1993 WL 13527, Counsel Stack Legal Research, https://law.counselstack.com/opinion/aaron-bravman-muriel-bravman-v-baxter-healthcare-corporation-ca2-1993.